UK markets open in 10 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
533.89+15.96 (+3.08%)
At close: 4:00PM EST
Show:
Income statement
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2019
31/12/2018
31/12/2017
Total revenue
9,243,500
7,863,400
6,710,800
5,872,227
Cost of revenue
1,005,600
782,200
434,100
397,061
Gross profit
8,237,900
7,081,200
6,276,700
5,475,166
Operating expenses
Research development
3,129,500
3,036,600
2,186,100
2,075,142
Selling general and administrative
1,987,200
1,834,800
1,556,200
1,320,433
Total operating expenses
5,152,600
4,871,400
3,742,300
3,395,575
Operating income or loss
3,085,300
2,209,800
2,534,400
2,079,591
Interest expense
48,800
30,200
28,200
25,119
Total other income/expenses net
439,100
249,500
47,300
24,039
Income before tax
3,475,600
2,429,100
2,553,500
2,078,511
Income tax expense
319,600
313,300
109,100
880,000
Income from continuing operations
3,156,000
2,115,800
2,444,400
1,198,511
Net income
3,156,000
2,115,800
2,444,400
1,198,511
Net income available to common shareholders
3,156,000
2,115,800
2,444,400
1,198,511
Basic EPS
-
19.38
22.65
11.27
Diluted EPS
-
18.46
21.29
10.34
Basic average shares
-
109,200
107,900
106,338
Diluted average shares
-
114,600
114,800
115,954
EBITDA
-
2,669,600
2,729,900
2,249,097